QX-31
QX-31 is an orally active selective NLRP3 inhibitor with a Kd value of 2.8 μM for hNLRP3. QX-31 inhibits PI3K/AKT and HIF-1α signaling. QX-31 shows anti-fibrotic effects in mouse models of unilateral ureteral obstruction and ischemia-reperfusion injury. QX-31 can be used for research on renal fibrosis.
For research use only. We do not sell to patients.
- CAS No.: 3065380-90-4
- Formula: C24H20FN3OS
- Molecular Weight:417.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
NLRP3 2.8 μM (Kd) |
HIF-1α |
In Vitro
QX-31 (0.312-10 μM) binds recombinant hNLRP3 with a KD of 2.8 μM in SPR[1].
QX-31 selectively binds the NLRP3 LRR domain with a KD of 1.25 μM by ITC[1].
QX-31 (1-10 μM) disrupts NEK7 recruitment and ASC oligomerization in THP-M cells[1].
QX-31 (1-10 μM) inhibits COL-I expression in kidney organoids[1].
QX-31 (5 μM) inhibited IL-1β secretion in THP-M cells with an IC50 of 1.28 μM[1].
QX-31 directly inhibits the NLRP3 activation phase and irreversibly inhibits IL-1β release in THP-M cells, with selectivity for AIM2, NLRC4, and NLRP1[1].
QX-31 attenuates inflammatory CM-induced profibrotic and glycolytic gene programs in HK-2 cells[1].
QX-31 inhibits PI3K/AKT/HIF-1α-related glycolysis and glutaminolysis in HK-2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | AUC0-t | AUC0-∞ | MRT0-t | MRT0-∞ | CLz | Vz | F | Tmax | Cmax | CLz/F | Vz/F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 50 mg/kg | p.o. | 28,282.10 min·ng/mL | 29,231.60 min·ng/mL | 204.2 min | 226.6 min | / | / | / | 8.3 min | 157.1 ng/mL | 1,835.8 mL/min/kg | 381,065.3 mL/kg |
| Mice[1] | 1 mg/kg | i.v. | 19,763.50 min·ng/mL | 20,614.70 min·ng/mL | 64.9 min | 126.6 min | 61.2 mL/min/kg | 4,850.47 mL/kg | 2.84 % | / | / | / | / |
In Vivo
QX-31 (12.5-50 mg/kg/day; p.o. (oral gavage); daily; 28 consecutive days following the initial ischemic insult) dose-dependently attenuates renal fibrosis in the IRI mouse model, reducing tubular injury, collagen deposition, myofibroblast activation, and profibrotic/inflammatory gene expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J[1]
-
Dosage:12.5 mg/kg/day; 25 mg/kg/day; 50 mg/kg/day
-
Administration:p.o. (intragastric gavage); daily; 14 consecutive days starting day 1 postsurgery
-
Result:Dose-dependently mitigated UUO-induced tubular injury and architectural damage.
It markedly reduced interstitial fibrotic burden by H&E and Masson staining and produced dose-responsive reductions in COL-I deposition and α-SMA-positive myofibroblast activation.
Suppressed FN and vimentin protein expression and downregulated proinflammatory/profibrotic genes Il6, Il1b, Tnfa, Col1a1, Col3a1, and Acta2.
QX-31 administration significantly blunted UUO-induced activation of the PI3K/AKT/HIF-1α axis and reduced protein levels of GLS1 and LDHA.
-
Animal Model:C57BL/6J[1]
-
Dosage:12.5 mg/kg/day; 25 mg/kg/day; 50 mg/kg/day
-
Administration:p.o. (oral gavage); daily; 28 consecutive days following the initial ischemic insult
-
Result:Dose-dependently ameliorated IRI-induced renal damage and structural distortion, with reduced tubular injury scores and diminished interstitial collagen deposition.
It produced dose-responsive reductions in COL-I accumulation and α-SMA myofibroblast activation.
Downregulated FN, vimentin, and α-SMA protein expression and suppressed transcription of Il6, Il1b, Tnfa, Col1a1, Col3a1, and Acta2.
In IRI kidneys, QX-31 blunted the PI3K/AKT/HIF-1α axis and reduced GLS1 and LDHA protein levels.
Chemical Information
-
CAS No. 3065380-90-4
-
Molecular Weight 417.50
-
Formula C24H20FN3OS
-
SMILES
FC(C=C1)=CC=C1CSC2=NC3=CC=CC=C3N2CC4=CC=C(NC(C=C)=O)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- QX-31
- 3065380-90-4
- QX31
- QX 31
- NOD-like Receptor (NLR)
- PI3K
- Akt
- HIF/HIF Prolyl-Hydroxylase
- AIM2
- ASC oligomerization
- IL-1β
- LRR domain
- NEK7
- NLRC4
- NLRP1
- NLRP3
- PI3K/AKT
- TGF-β
- collagen I
- glutaminolysis
- glycolysis
- human kidney organoids
- hypoxia-inducible factor alpha
- inflammasome
- ischemia-reperfusion injury
- mitochondrial membrane potential
- renal fibrosis
- unilateral ureteral obstruction
- Inhibitor
- inhibitor
- inhibit